natgillin/translations-raw huggingface dataset:
The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5- hydroxyl metabolite and no dosage adjustment is recommended.
Sočasno dajanje duloksetina (40 mg dvakrat na dan) poveča AUC tolterodina (2 mg dvakrat na dan) v stanju dinamičnega ravnovesja za 71 %, ne vpliva pa na farmakokinetiko njegovega aktivnega 5-hidroksi presnovka, zato ne priporočamo prilagajanja odmerjanja.
The co-administration of Eviplera and didanosine is not recommended (see section 4.4 and Table 1).
Sočasna uporaba zdravila Eviplera in didanozina ni priporočljiva (glejte poglavje 4.4 in preglednico 1).
The co-administration of midazolam with other sedative/hypnotic medicinal products and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
Sočasno dajanje midazolama z drugimi sedativnimi/hipnotičnimi zdravili in zaviralci osrednjega živčevja, vključno z alkoholom, bo verjetno okrepilo sedacijo in respiratorno depresijo.
The co-administration of Pandemic influenza vaccine H5N1 MedImmune with inactivated vaccines or with the seasonal vaccine Fluenz Tetra has not been studied.
Sočasna uporaba Cepiva proti pandemski gripi H5N1 MedImmune z inaktiviranimi cepivi ali s sezonskim cepivom Fluenz Tetra ni raziskana.
The co-administration of PDE5 inhibitors, including vardenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Sočasna uporaba zaviralcev PDE5, vključno z vardenafilom, s stimulatorji gvanilat-ciklaze, kot je riociguat, je kontraindicirana, saj lahko privede do simptomatske hipotenzije (glejte poglavje 4.5).
The co-administration of saxagliptin and CYP3A4/5 inducers, other than rifampicin (such as carbamazepine, dexamethasone, phenobarbital and phenytoin) has not been studied and may result in decreased plasma concentration of saxagliptin and increased concentration of its major metabolite.
Sočasna uporaba saksagliptina z drugimi induktorji CYP3A4/5 razen rifampicina (npr. s karbamazepinom, deksametazonom, fenobarbitalom in fenitoinom) ni raziskana; povzroči lahko znižanje koncentracije saksagliptina v plazmi in zvišanje koncentracije njegovega glavnega presnovka.
The co-administration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Sočasna uporaba saksagliptina in metformina je bila raziskana pri sladkornih bolnikih tipa 2, neustrezno urejenih s samim metforminom, in pri bolnikih, ki dotlej še niso prejemali zdravil, a so bili nezadostno urejeni samo z dieto in telesno dejavnostjo.
The co-administration of stavudine with REYATAZ is not expected to significantly alter the exposure of stavudine.
Pri sočasni uporabi stavudina in zdravila REYATAZ pomembnejših sprememb v izpostavljenosti stavudinu ne pričakujemo.
The co-administration of trivalent Fluenz with the live attenuated vaccines: measles, mumps, rubella, varicella, and orally-administered poliovirus has been studied.
Preučili so sočasno uporabo trivalentnega cepiva Fluenz z živimi oslabljenimi cepivi proti ošpicam, mumpsu, rdečkam, noricam in peroralnim cepivom proti otroški paralizi.
The co-primary efficacy endpoints of the study were progression-free survival (PFS) as assessed by an independent review committee (IRC) and overall survival (OS) (see Table 8 and Figures 1 to 2).
Ostali primarni cilji učinkovitosti v študiji so bili preživetje brez napredovanja bolezni (PFS – progression-free survival) po oceni neodvisnega odbora za pregled (IRC – independent review committee) in celokupno preživetje (OS – overall survival) (glejte preglednico 8 in sliki 1 in 2).
The co-primary endpoint was seroconversion rate (anti JEV antibody titer ≥1:10) and geometric mean titers (GMT) at Day 56 as assessed by a Plaque Reduction Neutralization Test (PRNT) for the entire study population.
Sočasna primarna končna točka je bil odstotek serokonverzije (titer protiteles proti virusu japonskega encefalitisa ≥1:10) in geometrični srednji titri na 56. dan, ocenjeni s testom Plaque Reduction Neutralization Test (PRNT) za celotno študijsko populacijo.
The co-primary endpoints for the efficacy analysis were:
Sočasni opazovani dogodki za analizo učinkovitosti so bili:
The co-primary endpoints in the placebo and active-controlled studies were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 “clear” or “almost clear” response versus placebo at Week 12 (see Tables 2 and 3).
Investigator's Global Assessment) z oceno "brez znakov" ali "skoraj brez znakov" v primerjavi z ustreznima deležema bolnikov, ki so prejemali placebo, z opazovanjem po 12 tednih zdravljenja (glejte preglednici 2 in 3).
The co-primary endpoints were the proportion of patients in clinical remission (CDAI < 150) at week 30 and time to loss of response through week 54.
Druga dva primarna končna rezultata sta bila: odstotek bolnikov v klinični remisiji (CDAI < 150) v tednu in čas do izginotja odziva na zdravilo v obdobju do 54. tedna.
The co-primary outcome measures were progression-free survival and OS.
Primarni merili učinkovitosti sta bili preživetje brez napredovanja bolezni in celokupno preživetje (OS).
The co-primary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl.
Koprimarna varnostna cilja sta bila prekinitev zdravljenja zaradi neželenega učinka in potrjeno zvišanje serumske koncentracije kreatinina za ≥ 0,5 mg/dl ali potrjena serumska koncentracija fosfata za < 2 mg/dl.
The coadministration of riociguat with Kaletra is not recommended (see section 4.4 and refer to riociguat SmPC).
Sočasna uporaba riociguata z zdravilom Kaletra ni priporočljiva (glejte poglavje 4.4 in glejte povzetek glavnih značilnosti zdravila za riociguat).
The coadministration of riociguat with Kaletra is not recommended (see section 4.4 and refer to riociguat SmPC).
Sočasna uporaba riociguata z zdravilom Kaletra ni priporočljiva (glejte poglavje 4.4 in glejte povzetek glavnih značilnosti zdravila za riociguat.)
The coadministration of riociguat with Norvir is not recommended (see section 4.4 and refer to riociguat SmPC).
Sočasna uporaba riociguata z zdravilom Norvir ni priporočljiva (glejte poglavje 4.4 in glejte povzetek glavnih značilnosti zdravila za riociguat).
The coadministration of saxagliptin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naive patients inadequately controlled on diet and exercise alone.
Sočasna uporaba saksagliptina in metformina je bila raziskana pri sladkornih bolnikih tipa 2, neustrezno urejenih s samim metforminom, in pri bolnikih, ki dotlej še niso prejemali zdravil, a so bili nezadostno urejeni samo z dieto in telesno dejavnostjo.
The coadministration of vorapaxar with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar SmPC).
Sočasna uporaba vorapaksarja z zdravilom Kaletra ni priporočljiva (glejte poglavje 4.4 in glejte povzetek glavnih značilnosti zdravila za vorapaksar).
The coadministration of vorapaxar with Norvir is not recommended (see section 4.4 and refer to the vorapaxar SmPC).
Sočasna uporaba vorapaksarja z zdravilom Norvir ni priporočljiva (glejte poglavje 4.4 in povzetek glavnih značilnosti zdravila za vorapaksar).
The coadministration of Zontivity with anticoagulants e.g., warfarin and new oral anticoagulants (NOACs), should be avoided. (See section 4.4.)
Sočasni uporabi zdravila Zontivity in antikoagulantov, npr. varfarina in novih peroralnih antikoagulantov, se je treba izogibati. (Glejte poglavje 4.4.)
The cognitive effects of ziconotide are typically reversible within 1 - 4 weeks after discontinuation of the medicinal product, but may persist in some cases.
Učinek zikonotida na kognitivne sposobnosti je običajno reverzibilen (stanje se popravi v 1 do 4 tednih), v posameznih primerih pa se lahko obdrži.
The cold form blister film is composed of polyvinyl chloride (PVC) film adhesively laminated to an oriented polyamide (OPA) film, adhesively laminated to aluminum foil, adhesively laminated to polyvinyl chloride (PVC) film.
Hladno stiskana folija pretisnega omota je sestavljena iz polivinilkloridnega (PVC) filma, ki je zlepljen in laminiran na usmerjen poliamidni (OPA) film, ta pa je zlepljen in laminiran na aluminjevo folijo, ki je zlepljena in laminirana na polivinilkloridni (PVC) film.
The collagen matrix is insoluble and consists of particles with a size range of 75-425µm.
Kolagenski matriks je netopen in je sestavljen iz delcev, velikih 75–425 µm.
The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation is unlikely to pose risk for local irritation with clinical use.
Skupna analiza zbranih podatkov iz predkliničnih in kliničnih študij draženja pri uporabi orodisperzibilnih tablet je pokazala, da pri tej formulaciji ni skoraj nikakršnega tveganja za lokalno draženje med klinično uporabo zdravila.
The colour and marking of the capsule is different for each strength (see table below).
Barva ovojnice kapsule je drugačna za vsako jakost (glejte tabelo spodaj).
The colour coding strip blue and the push button are at the bottom of the pen as it is held cap up.
Moder trak za razločevanje med jakostmi in pritisni gumb sta na dnu peresnika, če ga držite tako, da je pokrovček peresnika na vrhu.
The colour coding strip brown and the push button are at the bottom of the pen as it is held cap up.
Rjav trak za razločevanje med jakostmi in pritisni gumb sta na dnu peresnika, če ga držite tako, da je pokrovček peresnika na vrhu.
The colour coding strip pink and the push button are at the bottom of the pen as it is held cap up.
Rožnat trak za razločevanje med jakostmi in pritisni gumb sta na dnu peresnika, če ga držite tako, da je pokrovček peresnika na vrhu.
The colour of your iris may also go darker over time.
Prehodno lahko potemni tudi šarenica.
The coloured tab should be peeled back and the tablet should be removed gently.
Obarvani del naj odlušči in tableto previdno vzame ven.
The combination at a dose of 300 mg/5 mg also showed statistically significantly greater blood pressure reduction than aliskiren 300 mg monotherapy.
Tudi kombinacija v odmerku 300 mg/5 mg je statistično značilno bolj znižala krvni tlak kot monoterapija z aliskirenom v odmerku 300 mg.
The combination dose of dextromethorphan/quinidine increased steady state desipramine levels approximately 8-fold.
Kombinacija dekstrometorfana/kinidina je povečala stanje dinamičnega ravnovesja ravni dezipramina za približno 8-krat.
The combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not recommended.
Ni dokazano, da bi bila kombinacija zdravila Enbrel in anakinre klinično koristnejša, zato ni priporočljiva.
The combination gave a reduction of 1.22 points when metformin was given at 500 mg and a reduction of 1.59 points when metformin was given at 1,000 mg.
Z jemanjem kombinacije zdravil je prišlo do znižanja za 1,22 točke, kadar se je metformin dajal v odmerku 500 mg, in do zmanjšanja za 1,59 točke, kadar se je metformin dajal v odmerku
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Kombinacija lahko povzroči povečano tveganje za kardiovaskularne neželene učinke, povezane s salmeterolom, vključno z podaljšanim QT, palpitacijami in sinusno tahikardijo.
The combination of
Kombinacija
The combination of
Kombinacija zdravila
The combination of
Kombinacijo estrogenskih
The combination of
Pri sočasni uporabi zdravila
The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) and is not recommended in other patients (see sections 4.3, 4.4 and 5.1).
Pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR < 60 ml/min/1,73 m2) je uporaba kombinacije aliskirena z zaviralci angiotenzinskih receptorjev II ali z zaviralci angiotenzinske konvertaze kontraindicirana, pri drugih bolnikih pa ni priporočena (glejte poglavja 4.3, 4.4 in 5.1).
The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) and is not recommended in other patients (see sections 4.3, 4.4 and 5.1).
Pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73 m2) je uporaba kombinacije aliskirena z zaviralci angiotenzinskih receptorjev II ali z zaviralci angiotenzinske konvertaze kontraindicirana, pri drugih bolnikih pa ni priporočena (glejte poglavja 4.3, 4.4 in 5.1).
The combination of avanafil and
Uporaba avanafila v kombinaciji z
The combination of boosted
Kombinacija okrepljenega zdravila
The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-355 (BREATHE-2) and AC-052-356 (BREATHE-3).
Kombinacijo bosentana in epoprostenola so raziskovali v dveh študijah: AC-052-355 (BREATHE-2) in AC-052-356 (BREATHE-3).
The combination of Ceplene and interleukin-2 was more effective than no treatment in increasing the time until AML came back or the patient died: in the patients in their first complete remission, the average time without disease increased from 291 days with no treatment to 450 days after treatment with Ceplene and interleukin-2.
Kombinacija zdravila Ceplene in interlevkina-2 je bila v primerjavi z rezultati pri bolnikih, ki niso bili zdravljeni, učinkovitejša glede podaljšanja časa do ponovnega pojava akutne mieloidne levkemije ali smrti bolnika: pri bolnikih v prvi popolni remisiji se je povprečni čas brez bolezni podaljšal z 291 dni brez zdravljenja na 450 dni po zdravljenju z zdravilom Ceplene in interlevkinom-2.
The combination of Cholestagel and ezetimibe was more effective than ezetimibe taken with placebo: there was a fall of 32% in LDL-cholesterol levels in the patients taking Cholestagel and a fall of 21% in those taking placebo.
Kombinacija zdravila Cholestagel in ezetimiba je bila učinkovitejša od ezetimiba vzetega s placebom: ravni LDL-holesterola so se znižale za 32 % pri bolnikih, ki so jemali zdravilo Cholestagel, in za 21 % pri tistih, ki so jemali placebo.
The combination of clopidogrel/acetylsalicylic acid has no or negligible influence on the ability to drive and use machines.
Kombinacija klopidogrela/acetilsalicilna kisline ne vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
The combination of clopidogrel/acetylsalicylic acid is not recommended in this population.
Uporaba kombinacije klopidogrela/acetilsalicilne kisline se pri tej populaciji ne priporoča.
The combination of dabrafenib with trametinib has shown anti- tumour activity in BRAF V600 mutation positive melanoma cell lines in vitro and delays the emergence of resistance in vivo in BRAF V600 mutation positive melanoma xenografts.
Kombinacija dabrafeniba in trametiniba je pokazala protitumorsko aktivnost pri melanomskih celičnih linijah z mutacijo BRAF V600 in vitro, in vivo pa zakasni nastanek rezistence pri heterolognih melanomskih presadkih z mutacijo BRAF V600.
The combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate has been studied in 460 patients either as the fixed-dose combination tablet Atripla (study AI266073) or as the component products (study GS-01-934).
Kombinacijo efavirenza, emtricitabina in dizoproksiltenofovirijevega fumarata so preučevali pri 460 bolnikih bodisi kot kombinacijo tablet Atripla s fiksnim odmerkom (študija AI266073) ali kot posamične zdravilne učinkovine v zdravilu (študija GS-01-934).
the combination of elvitegravir
podatkov kombinacija elvitegravirja
The combination of emtricitabine, rilpivirine and tenofovir disoproxil fumarate has been studied as the component products in treatment-naïve patients (Phase III studies C209 and C215).
Kombinacijo emtricitabina, rilpivirina in dizoproksiltenofovirijevega fumarata so preučili kot posamične učinkovine zdravila pri predhodno nezdravljenih bolnikih (študiji faze III C209 in C215).
The combination of Entresto with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Kombinacija zdravila Entresto z zaviralcem ACE je kontraindicirana, ker povečuje tveganje za angioedem (glejte poglavje 4.3).
The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Kombinacija zdravila Entresto z neposrednim zaviralcem renina, kot je aliskiren, ni priporočena (glejte poglavje 4.5).
The combination of FORTEKOR PLUS and other anti-hypertensive agents (e.g. calcium channel blockers, -blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects.
Kombinacija zdravila FORTEKOR PLUS in drugih antihipertenzivnih zdravil (npr. zaviralcev kalcijevih kanalčkov, -blokatorjev ali diuretikov), anestetikov ali pomirjeval lahko povzroči aditivne hipotenzivne učinke.
The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”).
Kombinacija zdravila Humira in anakinre ni priporočljiva (glejte poglavje 4.4 “Sočasna uporaba bioloških DMARDS ali antagonistov TNF”).
The combination of Inflectra and abatacept is not recommended.
Kombiniranje zdravila Inflectra in abatacepta torej ni priporočljivo.
The combination of Inflectra with other biological therapeutics used to treat the same conditions as Inflectra, including anakinra and abatacept, is not recommended (see section 4.4).
Kombiniranje zdravila Inflectra z drugimi biološkimi zdravili za zdravljenje enakih bolezni kot z zdravilom Inflectra, vključno z anakinro in abataceptom, ni priporočljivo (glejte poglavje 4.4).
The combination of Invirase with ritonavir was assessed in 656 patients in two studies that compared Invirase with indinavir and with lopinavir (other antiviral medicines), both in combination with ritonavir and other antiviral medicines.
Kombinacijo zdravila Invirase z ritonavirjem so pri 656 bolnikih ocenjevali v dveh študijah, v katerih so zdravilo Invirase v kombinaciji z ritonavirjem in drugimi protivirusnimi zdravili enkrat primerjali z indinavirjem, drugič pa z lopinavirjem (drugima protivirusnima zdraviloma).
The combination of ivabradine 10 mg twice daily with St John’s Wort was shown to reduce ivabradine AUC by half.
Opazili so, da kombinacija ivabradina 10 mg dvakrat na dan s šentjanževko zmanjšuje njegovo površino pod krivuljo (AUC) za polovico.
The combination of Kaletra with atorvastatin is not recommended.
Sočasna uporaba zdravila Kaletra in simeprevirja ni priporočljiva.
The combination of Kaletra with atorvastatin is not recommended.
Sočasna uporaba zdravila Kaletra s tadalafilom ni priporočljiva.
The combination of Kaletra with:
Kombinacija zdravila Kaletra s/z:
The combination of lapatinib and trastuzumab may offer complementary mechanisms of action as well as possible non-overlapping mechanisms of resistance.
Kombinacija lapatiniba in trastuzumaba lahko učinkuje preko komplementarnih mehanizmov delovanja, lahko pa učinkuje tudi na neprekrivajoče se mehanizmev odpornosti.
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients).
Pri bolnikih z diseminiranim plazmocitomom je kombinacija lenalidomida in deksametazona povezana s povečano incidenco trombocitopenije 3. in 4. stopnje (9,9 % 3. stopnje in 1,4 % 4. stopnje pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 2,3 % 3. stopnje in 0,0 % stopnje pri bolnikih, ki so prejemali placebo/deksametazon).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8).
Pri bolnikih z diseminiranim plazmocitomom je kombinacija lenalidomida in deksametazona povezana s povečano incidenco trombocitopenije 3. in 4. stopnje (9,9 % 3. stopnje in 1,4 % 4. stopnje pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 2,3 % 3. stopnje in 0,0 % stopnje pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8).
Pri bolnikih z diseminiranim plazmocitomom je kombinacija lenalidomida in deksametazona povezana s povečano incidenco trombocitopenije 3. in 4. stopnje (9,9% 3. stopnje in 1,4% 4. stopnje pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 2,3% 3. stopnje in 0,0% 4. stopnje pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone- treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
Pri bolnikih z diseminiranim plazmocitomom z vsaj eno predhodno terapijo je kombinacija lenalidomida in deksametazona povezana s povečano incidenco nevtropenije 4. stopnje (5,1 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,6 % pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients with at least one prior therapy is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone- treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
Pri bolnikih z diseminiranim plazmocitomom z vsaj eno predhodno terapijo je kombinacija lenalidomida in deksametazona povezana s povečano incidenco nevtropenije 4. stopnje (5,1% pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,6% pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 3 and 4 thrombocytopenia (8.1 in Rd and Rd18 compared to 11% in MPT).
Kombinacija lenalidomida z deksametazonom v majhnem odmerku pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z zmanjšano incidenco trombocitopenije in 4. stopnje (8,1 % pri Rd in Rd18 v primerjavi z 11 % pri MPT).
The combination of lenalidomide with low dose dexamethasone in newly diagnosed multiple myeloma patients is associated with a decreased incidence of grade 4 neutropenia (8.5% in Rd and Rd18, compared with 15% in MPT).
Kombinacija lenalidomida z deksametazonom v majhnem odmerku pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z zmanjšano incidenco nevtropenije 4. stopnje (8,5 % pri Rd in Rd18, v primerjavi s 15 % pri MPT).